BCL2 and breast carcinoma: For example, in breast cancer, paclitaxel inhibits the PI3K/AKT signaling pathway, upregulates cleaved caspase-3 and Bax expression, and downregulates Bcl-2 expression, and the combination of the AKT inhibitor Capivasertib with paclitaxel significantly prolongs the progression-free survival and overall survival of breast cancer patients (Li et al., 2020).